What to know
- Discuss the FDA alert without assuming it identifies the clinic's product.
- Ask about ingredient suitability and sterile preparation.
- Require a clear purpose and evidence discussion rather than a wellness promise.
Understand the scope of the FDA alert
The FDA has warned compounders about using ingredients suitable for sterile compounding after learning of food-grade NAD+ being used to make intravenous products. An ingredient intended for food use should not be assumed suitable for a sterile injectable preparation. Appropriate ingredient quality and processing matter.
The agency reported adverse events after NAD+ injectable products, including severe chills, shaking, vomiting and fatigue, with some patients requiring medical treatment. It described these reactions as consistent with excessive endotoxins. The alert addresses a product-quality concern; it does not establish that every NAD product or any particular clinic's supply is contaminated.
Sources: FDA: Ingredients suitable for sterile compounding; FDA: Compounding questions and answers; Chicago Medspa service information
Ask about the actual preparation
Ask the clinician what product is proposed, who supplies it and what safeguards address ingredient suitability and sterile preparation. A product name or a wellness package cannot answer those questions. The relevant information concerns the preparation that would actually be administered.
The FDA's broader compounding guidance explains that compounded drugs do not undergo its premarket review for safety, effectiveness and quality. If the proposed product is compounded, discuss what that means for the decision. Registration or a professional setting should not be presented as proof of personal benefit.
Sources: FDA: Ingredients suitable for sterile compounding; FDA: Compounding questions and answers; Chicago Medspa service information
Separate the purpose from a promise
Ask what evidence supports the proposed use and what uncertainty remains. An appointment label does not demonstrate an anti-aging, detoxification or energy benefit. You should understand the intended clinical purpose, relevant alternatives and potential risks before deciding whether to proceed.
Clinical assessment, monitoring and follow-up arrangements should be explained by the treating professional. This article does not recommend NAD, set a dose or select a treatment schedule. It identifies questions raised by a specific FDA alert so that the quality and purpose of a proposed preparation can be discussed clearly during a wellness consultation.
Sources: FDA: Ingredients suitable for sterile compounding; FDA: Compounding questions and answers; Chicago Medspa service information
Sources and further reading
- FDA: Ingredients suitable for sterile compounding
- FDA: Compounding questions and answers
- Chicago Medspa service information
Manufacturer descriptions explain the product or technology. They do not replace an individual assessment or your provider’s instructions.